Cardinal Health is trading at $264.26, up 4.59% in pre-market; no confirmed company-specific announcement explaining the October 20 move was found.
- Cardinal Health’s October 16 study launch with Eli Lilly and October 1 binding letter of intent to extend pharmaceutical distribution agreements with CVS Health were not linked to the move.
- Supplied market indicators were mixed, with no clearly aligned broad-market move explaining the gain.
- Pre-market volume was unavailable in the reviewed sources.